2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 23:37, 14 December 2023
, 14 December 2023→Potential Longevity Benefits
No edit summary |
|||
| Line 126: | Line 126: | ||
! colspan="2" |Results of published human clinical trials | ! colspan="2" |Results of published human clinical trials | ||
|- | |- | ||
| style="vertical-align:top; border:none;" | <br>[[File:NMN NAD+ Mice.png|frameless|100px]] | | style="vertical-align:top; border:none;" | <br>[[File:NMN NAD+ Mice.png|frameless|100px|alt=A simplified diagram showing the relationship between NMN and NAD+ in a mouse model. An arrow points downward from 'NMN' to a circular graphic with a silhouette of a mouse, inside which is 'NAD+' with an upward-pointing red arrow, indicating an increase in NAD+ levels when NMN is administered.]] | ||
| style="vertical-align:top; border-left: none;" | | | style="vertical-align:top; border-left: none;" | | ||
* '''Brain''': improved brain function, protected from neurodegeneration{{pmid|27130898}}{{pmid|35057482}}{{pmid|35593333}}{{pmid|31678348}}{{pmid|27425894}}, enhanced new myelin generation{{pmid|35264567}} | * '''Brain''': improved brain function, protected from neurodegeneration{{pmid|27130898}}{{pmid|35057482}}{{pmid|35593333}}{{pmid|31678348}}{{pmid|27425894}}, enhanced new myelin generation{{pmid|35264567}} | ||